Clinical Trials Logo

Neoplasms, Hormone-dependent clinical trials

View clinical trials related to Neoplasms, Hormone-dependent.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00267553 Terminated - Breast Neoplasms Clinical Trials

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Start date: November 2005
Phase: Phase 3
Study type: Interventional

Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (Fareston®), to the single agent FDA-approved aromatase inhibitor letrozole (Femara®) for the treatment of advanced breast cancer. The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of atamestane, plus toremifene (Fareston®), is more effective than letrozole (Femara®) in delaying the growth of breast cancer.

NCT ID: NCT00097344 Terminated - Breast Neoplasms Clinical Trials

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.